The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders

Journal of Clinical Nursing

Volumn 20, Issue 15-16, 2011, Pages 2172-2182

  Chiang, Yan Ling ^a   Klainin Yobas, Piyanee ^a   Ignacio, Jeanette ^a   Chng, Cecilia Mui Lee ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Antipsychotic side effects; Attitudes towards medication; Nurses; Nursing; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 79960347960     PISSN: 09621067     EISSN: 13652702     Source Type: Journal    
DOI: 10.1111/j.1365-2702.2010.03659.x     Document Type: Article

References (45)

1. Adams CE, Fenton MK, Quraishi S & David AS (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179, 290-299.
2. Adewuya AO, Ola BA, Mosaku SK, Fatoye FO & Eegunranti AB (2006) Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatrica Scandinavica 113, 207-211.
3. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, Washington DC.
4. Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 19, 609-618.
5. Bezchlibnyk-Butler KZ, Jeffries JJ & Virani A (2007) Clinical Handbook of Psychotropic Drugs, 17th edn. Hogrefe & Huber Publishers, Canada.
6. Bhavnani SM & Levin GM (1996) Antipsychotic agents: a survey of the prevalence, severity and burden of side-effects. International Clinical Psychopharmacology 11, 1-12.
7. Bollini P, Pampallona S, Orza MJ, Adams ME & Chalmers TC (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine 24, 307-316.
8. Brace N, Kemp D & Snelgar R (2006) SPSS for Psychologists: A Guide to Data Analysis Using SPSS for Windows, 3rd edn. Palgrave Macmillan, London.
9. Cabeza IG, Amador MS, Lopez CA & de Chavez MG (2000) Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophrenia Research 41, 349-355.
10. Castle D, Morgan V & Jablensky A (2002) Antipsychotic use in Australia: the patients' perspective. Australian and New Zealand Journal of Psychiatry 36, 633-641.
11. Chong SA (2004) A risk reduction approach for schizophrenia: the early psychosis intervention programme. Annals of the Academy of Medicine, Singapore 33, 630-635.
12. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum, Hillsdale.
13. Day JC, Wood G, Dewey M & Bentall RP (1995) A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650-653.
14. Day JC, Kinderman P & Bentall RP (1998) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica 97, 93-97.
15. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P & Power C (2005) Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 62, 717-724.
16. Fakhoury WKH, Wright D & Wallace M (2001) Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline. International Clinical Psychopharmacology 16, 153-162.
17. Field A (2009) Discovering Statistics Using SPSS, 3rd edn. Sage Publications, London.
18. Fleischhacker WW, Oehl MA & Hummer M (2003) Factors influencing compliance in schizophrenia patients. Journal of Clinical Psychiatry 64, 10-13.
19. Freudenreich O, Cather C, Evins AE, Henderson DC & Goff DC (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Journal of Clinical Psychiatry 65, 1372-1376.
20. Fuller MA & Sajatovic M (2007) Drug Information Handbook for Psychiatry, 6th edn. Lexi-Comp, Hudson.
21. Geddes J, Freemantle N, Harrison P & Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371-1376.
22. Gervin M, Browne S, Garavan J, Roe M, Larkin C & O'Callaghan E (1999) Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side-effects and symptomatology. European Psychiatry 14, 405-409.
23. Gray R, Bressington D, Lathlean J & Mills A (2008) Relationship between adherence, symptoms, treatment attitudes, satisfaction, and side-effects in prisoners taking antipsychotic medication. Journal of Forensic Psychiatry and Psychology 19, 335-351.
24. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M & Fleischhacker WW (2002) Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. Journal of Clinical Psychiatry 63, 49-53.
25. Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG & Fleischhacker WW (2007) Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatrica Scandinavica 116, 354-361.
26. Hogan TP, Awad AG & Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 13, 177-183.
27. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY & Yoon JS (2006) Association between attitude toward medication and neurocognitive function in schizophrenia. Clinical Neuropharmacology 29, 197-205.
28. Kline RB (1998) Principal and Practice of Structural Equation Modeling. Guilford Press, New York.
29. Kuroda N, Sun S, Lin CK, Morita N, Kashiwase H, Yang F & Nakatani Y (2008) Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing. Environmental Health and Preventive Medicine 13, 288-295.
30. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D & Naber D (2004) Impact of present and past antipsychotic side-effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry 19, 415-422.
31. Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G & Collings P (2000) The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australia and New Zealand Journal of Mental Health Nursing 9, 166-176.
32. Patel MX, De ZoysaN, Bernadt M & David A (2009) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Journal of Psychopharmacology 23, 789-796.
33. Ritsner M, Perelroyzen G, Ilan H & Gibel A (2004) Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of Clinical Psychopharmacology 24, 245-254.
34. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D & Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56, 241-247.
35. Sadock BJ (2007) Kaplan & Sadock's Synopsis of Psychiatry: Behavioural Sciences/Clinical Psychiatry, 10th edn. Wolter Kluwer/Lippincott Williams & Wilkins, Philadelphia.
36. Schatzberg AF, Cole JO & DeBattista C (2007) Manual of Clinical Psychopharmacology, 6th edn. American Psychiatric Publishing Inc., Washington DC.
37. Stahl SM (2008) Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edn. Cambridge University Press, New York.
38. Stuart GW (2008) Principles and Practice of Psychiatric Nursing, 9th edn. Mosby Elsevier, Philadelphia.
39. Taylor D, Paton C & Kerwin R (2007) The Maudsley Prescribing Guidelines, 9th edn. Informa Healthcare, UK.
40. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S & Awad A (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43, 135-145.
41. Walker H & MacAulay K (2005) Assessment of the side-effects of antipsychotic medication. Nursing Standard 19, 41-46.
42. Weiden PJ & Miller AL (2001) Which side-effects really matter? Screening for common and distressing side-effects of antipsychotic medications. Journal of Psychiatric Practice 7, 41-47.
43. Wolters HA, Knegtering H, van denBosch RJ & Wiersma D (2009) Effects and side-effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophrenia Research 112, 114-118.
44. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667.
45. Yorston G & Pinney A (2000) Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatric Bulletin 24, 130-132.